Journal: ACS Omega

Article Title: Implementation of the QbD Approach to the Analytical Method Development and Validation for the Estimation of the Treprostinil Injection Dosage Form by RP-HPLC

doi: 10.1021/acsomega.5c00373

Figure Lengend Snippet: Chemical structure of treprostinil.

Article Snippet: Treprostinil was obtained as a gifted sample from Dr. Reddy’s Laboratories.

Techniques:

Journal: ACS Omega

Article Title: Implementation of the QbD Approach to the Analytical Method Development and Validation for the Estimation of the Treprostinil Injection Dosage Form by RP-HPLC

doi: 10.1021/acsomega.5c00373

Figure Lengend Snippet: Final optimized solution for treprostinil injection.

Article Snippet: Treprostinil was obtained as a gifted sample from Dr. Reddy’s Laboratories.

Techniques: Injection

Journal: ACS Omega

Article Title: Implementation of the QbD Approach to the Analytical Method Development and Validation for the Estimation of the Treprostinil Injection Dosage Form by RP-HPLC

doi: 10.1021/acsomega.5c00373

Figure Lengend Snippet: Optimized chromatogram of treprostinil injection.

Article Snippet: Treprostinil was obtained as a gifted sample from Dr. Reddy’s Laboratories.

Techniques: Injection

Journal: ACS Omega

Article Title: Implementation of the QbD Approach to the Analytical Method Development and Validation for the Estimation of the Treprostinil Injection Dosage Form by RP-HPLC

doi: 10.1021/acsomega.5c00373

Figure Lengend Snippet: BAGI pictogram for treprostinil injection.

Article Snippet: Treprostinil was obtained as a gifted sample from Dr. Reddy’s Laboratories.

Techniques: Injection

Journal: Biomedicines

Article Title: The Importance of Dose Escalation in the Treatment of Pulmonary Arterial Hypertension with Treprostinil

doi: 10.3390/biomedicines13010172

Figure Lengend Snippet: Reasons for the discontinuation of treprostinil treatment within the first 12 months of treatment. EPO—epoprostenol; LTx—lung transplantation.

Article Snippet: This is a retrospective observational study that aims to assess a group of patients treated with treprostinil (Tresuvi ® (Amomed, Vienna, Austria), Remodulin ® (Ferrer International, Barcelona, Spain)) for PAH as an addition to existing PAH-targeted therapy or as up-front therapy between 2012 and 2022.

Techniques: Transplantation Assay

Journal: Biomedicines

Article Title: The Importance of Dose Escalation in the Treatment of Pulmonary Arterial Hypertension with Treprostinil

doi: 10.3390/biomedicines13010172

Figure Lengend Snippet: Improvement in functional and biochemical parameters after 12 months of treatment in subgroups of patients who achieved a dose of treprostinil >19.8 ng/kg/min vs. those who received a dose ≤19.8 ng/kg/min after 3 months of treatment.

Article Snippet: This is a retrospective observational study that aims to assess a group of patients treated with treprostinil (Tresuvi ® (Amomed, Vienna, Austria), Remodulin ® (Ferrer International, Barcelona, Spain)) for PAH as an addition to existing PAH-targeted therapy or as up-front therapy between 2012 and 2022.

Techniques: Functional Assay

Journal: Biomedicines

Article Title: The Importance of Dose Escalation in the Treatment of Pulmonary Arterial Hypertension with Treprostinil

doi: 10.3390/biomedicines13010172

Figure Lengend Snippet: Improvement in functional and biochemical parameters after 12 months of treatment in subgroups of patients who achieved a dose of treprostinil >19.8 ng/kg/min vs. those who received a dose ≤19.8 ng/kg/min after 3 months of treatment.

Article Snippet: This is a retrospective observational study that aims to assess a group of patients treated with treprostinil (Tresuvi ® (Amomed, Vienna, Austria), Remodulin ® (Ferrer International, Barcelona, Spain)) for PAH as an addition to existing PAH-targeted therapy or as up-front therapy between 2012 and 2022.

Techniques: Functional Assay

Journal: Biomedicines

Article Title: The Importance of Dose Escalation in the Treatment of Pulmonary Arterial Hypertension with Treprostinil

doi: 10.3390/biomedicines13010172

Figure Lengend Snippet: Spearman’s correlation coefficients for treprostinil dose achieved in subsequent escalation stages and clinical parameters.

Article Snippet: This is a retrospective observational study that aims to assess a group of patients treated with treprostinil (Tresuvi ® (Amomed, Vienna, Austria), Remodulin ® (Ferrer International, Barcelona, Spain)) for PAH as an addition to existing PAH-targeted therapy or as up-front therapy between 2012 and 2022.

Techniques:

Journal: Pharmaceutics

Article Title: Pharmacological Treatment of Interstitial Lung Diseases: A Novel Landscape for Inhaled Agents

doi: 10.3390/pharmaceutics16111391

Figure Lengend Snippet: Pharmacological inhaled agents with antifibrotic properties: in vivo studies.

Article Snippet: Treprostinil (L606) , PH-ILD , Liposomal (L606) , Liquidia Technologies, Inc. , Phase III Recruiting , 07/2025 , NCT04691154.

Techniques: In Vivo, Aerosol, Clinical Proteomics

Journal: Pharmaceutics

Article Title: Pharmacological Treatment of Interstitial Lung Diseases: A Novel Landscape for Inhaled Agents

doi: 10.3390/pharmaceutics16111391

Figure Lengend Snippet: Current inhaled agents under investigation in ILDs: recruiting trials.

Article Snippet: Treprostinil (L606) , PH-ILD , Liposomal (L606) , Liquidia Technologies, Inc. , Phase III Recruiting , 07/2025 , NCT04691154.

Techniques: